Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 5, 2009, Pages 568-575

  Sasaki, Hidehisa ^a   Saiki, Atsuhito ^b   Endo, Kei ^b   Ban, Noriko ^b   Yamaguchi, Takashi ^b   Kawana, Hidetoshi ^b   Nagayama, Daizi ^b   Ohhira, Masahiro ^b   Oyama, Tomokazu ^b   Miyashita, Yoh ^b   Shirai, Kohji ^b  

^a Chiba University   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Cardio ankle vascular index; Diabetic nephropathy; Efonidipine; Oxidative stress; T type calcium channel blocker

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CANDESARTAN; CREATININE; EFONIDIPINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PULSE RATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 73249126058     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1628     Document Type: Article

References (48)

1. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M: Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res, 2005; 28: 889-894
2. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H: Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res, 2007; 30: 621-626
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003; 108: 2154-2169
4. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: The burden of kidney disease: improving global outcomes. Kidney Int, 2004; 66: 1310-1314
5. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39: S1-S266
6. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of communitybased studies. J Am Soc Nephrol, 2004; 15: 1307-1315
7. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb, 2006; 13: 101-107
8. Yambe T, Meng X, Hou X, Wang Q, Sekine K, Shiraishi Y, Watanabe M, Tamaguchi T, Shibata M, Kuwayama T, Maruyama M, Konno S, Nitta S: Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. Biomed Pharmacother, 2005; 59 (Suppl 1): S177-S179
9. Kubozono T, Miyata M, Ueyama K, Nagaki A, Otsuji Y, Kusano K, Kubozono O, Tei C: Clinical significance and reproducibility of new arterial distensibility index. Circ J, 2007; 71: 89-94
10. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H: Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J, 2008; 72: 598-604
11. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, Watanabe H: Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterols. J Clin Lab Anal, 1992; 11: 82-86
12. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S: Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol, 2007; 11: 41-50
13. American Diabetes Association: Nephropathy in diabetes, Diabetes Care, 27 (Suppl. 1) (2004), pp. S79-S83
14. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, Hiai H, Ochi H, Osawa T: Quantitative immunohistochemical determination of 8-hydroxy-2' deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest, 1997; 76: 365-374
15. Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K, Takamatsu I, Ozawa Y, Saruta T: Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens, 2001; 19: 2031-2037
16. Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T: Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res, 2007; 30: 797-806
17. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens, 2005; 1: 44-49
18. + and atrial natriuretic peptide. Am J Physiol, 1991; 261: F706-719
19. Rossier MF, Ertel EA, Vallotton MB, Capponi AM: Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther, 1998; 287: 824-831
20. Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, Nakajima T, Horii M, Uemura S, Saito Y: Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol, 2006; 47: 133-138
21. Okayama S, Imagawa K, Naya N, Iwama H, Somekawa S, Kawata H, Horii M, Nakajima T, Uemura S, Saito Y: Blocking T-type Ca2?? channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res, 2006; 29: 493-497
22. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M: Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res, 2007; 30: 691-697
23. Baynes JW, Thorpe SR: The role of oxidative stress in diabetic complications. Curr Opin Endocrinol, 1997; 3: 277-284
24. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJM, Gispen WH, Bravenboer B: The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev, 1995; 11: 181-192
25. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications. Diabetes, 1999; 48: 1-9
26. Shigenaga MK, Gimeno CJ, Ames BN: Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA, 1989; 86: 9697-9701
27. Mak TI, Boehme P, Weglicki WB: Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circ Res, 1992; 70: 1099-1103
28. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens Res, 2004; 27: 877-885
29. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J: Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res, 2005; 28: 107-112
30. Safar ME, London GM, Plante GE: Arterial stiffness and kidney function. Hypertension, 2004; 43: 163-168
31. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME: Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int, 2001; 59: 1834-1841
32. Wang MC, Tsai WC, Chen JY, Huang JJ: Stepwise increase in arterial stiffness corresponding with the stages of chronic Kidney disease. Am J Kidney Dis, 2005; 45: 494-501
33. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2005; 67: 2089-2100
34. Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Hiratsuka A, Matsuzaki M: Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res, 2008; 31: 1347-1355
35. Schiffrin EL, Lipmann ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007; 116: 85-97
36. Stam F, van Guldener C, Becker A, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study. J Am Soc Nephrol, 2006; 17: 537-545
37. Amabile N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol, 2005; 16: 3381-3388
38. Fan J, Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb, 2003; 10: 63-71
39. Lei YC, Hwang JS, Chan CC, Lee CT, Cheng TJ: Enhanced oxidative stress and endothelial dysfunction in streptozotocin-diabetic rats exposed to fine particles. Environ Res, 2005; 99: 335-343
40. Tsuchiya K, Nakayama C, Iwashima F, Sakai H, Izumiyama H, Doi M, Hirata Y: Advanced endothelial dysfunction in diabetic patients with multiple risk factors; importance of insulin resistance. J Atheroscler Thromb, 2007; 14: 303-309
41. Endemann DH, Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol, 2004; 15: 1983-1992
42. 2+ channels. Science, 2003; 302: 1416-1418
43. Vanbavel E, Sorop O, Andreasen D, Pfaffendorf M, Jensen BL: Role of T-type calcium channels in myogenic tone of skeletal muscle resistance arteries. Am J Physiol Circ Physicl, 2002; 283: H2239-H2243
44. 2+- and volume-activated Cl- channels in macrovascular endothelial cells. Br J Pharmacol, 1997; 121: 547-555
45. Shinohara K, Shoji T, Kimoto E, Yokoyama H, Fujiwara S, Hatsuda S, Maeno T, Shoji T, Fukumoto S, Emoto M, Koyama H, Nishizawa Y: Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2005; 12: 205-210
46. Hongo M, Tsutsui H, Mawatari E, Hidaka H, Kumazaki S, Yazaki Y, Takahashi M, Kinoshita O, Ikeda U: Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J, 2008; 72: 722-728
47. Matsuo T, Iwade K, Hirata N, Yamashita M, Ikegami H, Tanaka N, Aosaki M, Kasanuki H: Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels, 2005; 20: 8-12
48. Endo K, Miyashita Y, Sasaki H, Ebisuno M, Ohira M, Saiki A, Koide N, Oyama T, Takeyoshi M, Shirai K: Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb, 2006; 13: 68-75